Reaction

Skin Weeping reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,283 reports · 59 co-occurring drugs

As of the last recalculation, Skin Weeping appears in 3,283 FAERS reports alongside 59 co-occurring drug terms. The strongest observed disproportionality signal is DUPILUMAB (PRR 61.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Dupilumab	1,946	61.4	61.7
Mometasone	139	50.1	50.5
Nemolizumab-Ilto	86	44.0	44.3
Clobetasol Propionate Ointment Usp, 0.05%	53	33.1	33.3
Clobetasol Propionate	53	33.0	33.2
Triamcinolone Acetonide Ointment Usp, 0.05%	81	22.5	22.5
Mupirocin	41	19.5	19.6
Mupirocin Calcium	41	19.1	19.2
Hydrocortisone 1%	191	19.1	19.1
Hydrocortisone Cream	190	18.9	19.0
Anti-Itch	188	18.8	18.8
Anti-Pruritic	188	18.8	18.8
Antipruritic (Anti-Itch)	188	18.8	18.8
Cool Relief Gel With Aloe	188	18.8	18.8
Drs. Hydrocortisone	188	18.8	18.8
Hydrocortisone Continuous Spray	188	18.8	18.8
Hydrocortisone Spray	188	18.8	18.8
Anti-Itch Cream	188	18.8	18.8
Hydrocortisone Lotion	188	18.8	18.8
Hydrocortisone Cream 1%	188	18.8	18.8
Hydrocortisone Cream 1/2%	188	18.8	18.8
Hydrocortisone Acetate	193	17.8	17.9
Mometasone Furoate	109	17.1	17.2
Triamcinolone Acetonide	79	16.6	16.6
Hydrocortisone	199	15.0	15.0
Fexofenadine Hcl	20	13.8	13.8
Crisaborole	17	11.3	11.3
Fexofenadine Hydrochloride	34	10.0	10.0
Ketoconazole	25	9.2	9.2
Ketoconazole Foam	21	9.1	9.1
Ketoconazole Cream, 2%	21	9.0	9.0
Hydroxyzine Hydrochloride	18	8.7	8.7
Hydroxyzine Hydrochloride Oral	18	8.7	8.7
Fexofenadine	22	8.5	8.5
Tretinoin	9	7.0	7.1
Levocetirizine Dihydrochloride	25	6.6	6.6
Hydroxyzine	48	6.5	6.5
Cetirizine Hcl	9	6.2	6.2
Oxybutynin Chloride	7	5.1	5.1
Azelastine	14	5.0	5.0
Fenofibrate	27	4.9	4.9
Vibegron	6	4.8	4.8
Eplerenone	9	4.5	4.5
Isosorbide Mononitrate	14	4.3	4.3
Tacrolimus Ointment 0.1%	76	3.9	3.9
Atorvastatin Calcium, Film Coated	43	3.9	3.9
Tacrolimus Extended-Release Capsules	75	3.9	3.9
Miconazole Nitrate	5	3.6	3.6
Upadacitinib	41	3.2	3.2
Fremanezumab-Vfrm	5	2.8	2.8
Daptomycin	4	2.8	2.8
Regorafenib	5	2.7	2.7
Budesonide, Glycopyrrolate, And Formoterol Fumarate	4	2.4	2.4
Bimekizumab	8	2.4	2.4
Secukinumab	59	2.3	2.3
Apalutamide	3	1.6	1.6
Ixekizumab	7	1.2	1.2
Salicylic Acid	4	0.5	0.5
Adapalene	10	0.3	0.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.